ARQT icon

Arcutis Biotherapeutics

279 hedge funds and large institutions have $3.75B invested in Arcutis Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 102 increasing their positions, 76 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
279
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$21.1M
Puts
$2.6M
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
MCM
276
MAI Capital Management
Ohio
$465
PA
277
Parallel Advisors
California
$58
RFP
278
Root Financial Partners
California
$29
TC
279
Tejara Capital
United Kingdom
PHS
280
PFM Health Sciences
California
JGC
281
J. Goldman & Co
New York
SAM
282
Simplify Asset Management
Nevada
ABG
283
Ally Bridge Group
New York
APM
284
Avidity Partners Management
Texas
VPC
285
Vestal Point Capital
New York
SSA
286
Schonfeld Strategic Advisors
New York
Stifel Financial
287
Stifel Financial
Missouri
CCIA
288
Campbell & Co Investment Adviser
Maryland
YIH
289
Y-Intercept (HK)
Hong Kong
GCM
290
Graham Capital Management
Connecticut
DC
291
Diametric Capital
Massachusetts
BHCM
292
Brevan Howard Capital Management
Jersey
BCM
293
Bayesian Capital Management
New York
TI
294
Trexquant Investment
Connecticut
OAC
295
OMERS Administration Corp
Ontario, Canada
PA
296
PharVision Advisers
Florida
CPC
297
Cookson Peirce & Co
Pennsylvania
WC
298
Wexford Capital
Florida
FDCDDQ
299
Federation des caisses Desjardins du Quebec
Quebec, Canada
JIC
300
Johnson Investment Counsel
Ohio